已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

西妥昔单抗 医学 多西紫杉醇 肿瘤科 内科学 卡铂 顺铂 头颈部 氟尿嘧啶 头颈部癌 化疗 放射治疗 癌症 外科 结直肠癌
作者
J. Guigay,Anne Aupérin,Jérôme Fayette,Esma Saada‐Bouzid,Cédrik Lafond,Miren Taberna,Lionnel Geoffrois,Laurent Martin,Olivier Capitain,Didier Cupissol,Hélène Castanie,Damien Vansteene,Philippe Schafhausen,Alison Johnson,Caroline Even,Christian Sire,Sophie Duplomb,Camille Evrard,Jean‐Pierre Delord,Brigitte Laguerre
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (4): 463-475 被引量:165
标识
DOI:10.1016/s1470-2045(20)30755-5
摘要

Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–platinum–cetuximab) showed promising results, with a median overall survival of 14·0 months in first-line recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). We therefore aimed to compare the efficacy and safety of the TPEx regimen with the standard of care EXTREME regimen (platinum–fluorouracil–cetuximab) in this setting. Methods This was a multicentre, open-label, randomised, phase 2 trial, done in 68 centres (cancer centres, university and general hospitals, and private clinics) in France, Spain, and Germany. Eligible patients were aged 18–70 years with histologically confirmed recurrent or metastatic HNSCC unsuitable for curative treatment; had at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1; and had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less. Participants were randomly assigned (1:1) using the TenAlea website by investigators or delegated clinical research associates to the TPEx regimen or the EXTREME regimen, with minimisation by ECOG performance status, type of disease evolution, previous cetuximab treatment, and country. The TPEx regimen consisted of docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both intravenously on day 1, and cetuximab on days 1, 8, and 15 (intravenously 400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently). Four cycles were repeated every 21 days with systematic granulocyte colony-stimulating factor (G-CSF) support at each cycle. In case of disease control after four cycles, intravenous cetuximab 500 mg/m2 was continued every 2 weeks as maintenance therapy until progression or unacceptable toxicity. The EXTREME regimen consisted of fluorouracil 4000 mg/m2 on day 1–4, cisplatin 100 mg/m2 on day 1, and cetuximab on days 1, 8, and 15 (400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently) all delivered intravenously. Six cycles were delivered every 21 days followed by weekly 250 mg/m2 cetuximab as maintenance therapy in case of disease control. G-CSF support was not mandatory per the protocol in the EXTREME regimen. The primary endpoint was overall survival in the intention-to-treat population; safety was analysed in all patients who received at least one dose of chemotherapy or cetuximab. Enrolment is closed and this is the final analysis. This study is registered at ClinicalTrials.gov, NCT02268695. Findings Between Oct 10, 2014, and Nov 29, 2017, 541 patients were enrolled and randomly assigned to the two treatment regimens (271 to TPEx, 270 to EXTREME). Two patients in the TPEx group had major deviations in consent forms and were not included in the final analysis. Median follow-up was 34·4 months (IQR 26·6–44·8) in the TPEx group and 30·2 months (25·5–45·3) in the EXTREME group. At data cutoff, 209 patients had died in the TPEx group and 218 had died in the EXTREME group. Overall survival did not differ significantly between the groups (median 14·5 months [95% CI 12·5–15·7] in the TPEx group and 13·4 months [12·2–15·4] in the EXTREME group; hazard ratio 0·89 [95% CI 0·74–1·08]; p=0·23). 214 (81%) of 263 patients in the TPEx group versus 246 (93%) of 265 patients in the EXTREME group had grade 3 or worse adverse events during chemotherapy (p<0·0001). In the TPEx group, 118 (45%) of 263 patients had at least one serious adverse event versus 143 (54%) of 265 patients in the EXTREME group. 16 patients in the TPEx group and 21 in the EXTREME group died in association with adverse events, including seven patients in each group who had fatal infections (including febrile neutropenia). Eight deaths in the TPEx group and 11 deaths in the EXTREME group were assessed as treatment related, most frequently sepsis or septic shock (four in each treatment group). Interpretation Although the trial did not meet its primary endpoint, with no significant improvement in overall survival with TPEx versus EXTREME, the TPEx regimen had a favourable safety profile. The TPEx regimen could provide an alternative to standard of care with the EXTREME regimen in the first-line treatment of patients with recurrent or metastatic HNSCC, especially for those who might not be good candidates for up-front pembrolizumab treatment. Funding Merck Santé and Chugai Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
抠鼻公主完成签到 ,获得积分10
1秒前
张宝完成签到,获得积分10
1秒前
丘比特应助清逸采纳,获得10
1秒前
tdtk发布了新的文献求助10
2秒前
盼盼发布了新的文献求助10
4秒前
momo完成签到,获得积分10
8秒前
小二郎应助小木安华采纳,获得10
9秒前
atmcymed完成签到,获得积分10
10秒前
欣喜的人龙完成签到 ,获得积分10
11秒前
Song完成签到,获得积分10
12秒前
科研通AI2S应助tdtk采纳,获得10
13秒前
直觉应助黎乐荷采纳,获得10
13秒前
华仔应助黎乐荷采纳,获得10
13秒前
pinklay完成签到 ,获得积分10
13秒前
小聖完成签到 ,获得积分10
15秒前
mov完成签到,获得积分10
16秒前
Stardust完成签到,获得积分10
17秒前
wansida完成签到,获得积分10
20秒前
Bingtao_Lian完成签到 ,获得积分10
21秒前
Joaquin完成签到 ,获得积分10
22秒前
2224270676完成签到,获得积分10
24秒前
小王爱看文献完成签到 ,获得积分10
29秒前
chenwuhao完成签到 ,获得积分10
29秒前
科研达人发布了新的文献求助10
30秒前
书文混四方完成签到 ,获得积分10
30秒前
QMCL完成签到,获得积分0
30秒前
艺术家完成签到 ,获得积分10
30秒前
直觉完成签到,获得积分20
30秒前
单薄绿竹完成签到,获得积分10
32秒前
超级小熊猫完成签到 ,获得积分10
32秒前
温暖妙彤完成签到 ,获得积分10
32秒前
路灯下的小伙完成签到,获得积分10
33秒前
33秒前
梅西完成签到 ,获得积分10
35秒前
急雪回风完成签到,获得积分10
36秒前
RYYYYYYY233完成签到 ,获得积分10
36秒前
清逸发布了新的文献求助10
37秒前
Hairee完成签到,获得积分10
38秒前
38秒前
laomuxile发布了新的文献求助10
39秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989957
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11255966
捐赠科研通 3270856
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882252
科研通“疑难数据库(出版商)”最低求助积分说明 809216